Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France

BACKGROUND: Based on the results of the phase III randomized 20120215 trial, the European Medicines Agency granted the approval of blinatumomab for the treatment of pediatric patients with high-risk first-relapsed Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL)....

Descripción completa

Detalles Bibliográficos
Autores principales: Caillon, Megane, Brethon, Benoit, van Beurden-Tan, Chrissy, Supiot, Romain, Le Mezo, Antoine, Chauny, Jean-Vannak, Majer, Istvan, Petit, Arnaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333169/
https://www.ncbi.nlm.nih.gov/pubmed/37071263
http://dx.doi.org/10.1007/s41669-023-00411-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333169/
https://www.ncbi.nlm.nih.gov/pubmed/37071263
http://dx.doi.org/10.1007/s41669-023-00411-4

Ejemplares similares